Cited by 1,217Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, Francesca, Solomon, Alina, Winblad, Bengt, Mecocci, Patrizia, Kivipelto, Miia·2010·The Lancet Neurology

DOI 10.1016/s1474-4422(10)70119-8

Open this paper in CoChat — free account

Abstract

Alzheimer's disease is the most common cause of dementia in elderly people. Research into Alzheimer's disease therapy has been at least partly successful in terms of developing symptomatic treatments, but has also had several failures in terms of developing disease-modifying therapies. These successes and failures have led to debate about the potential deficiencies in our understanding of the pathogenesis of Alzheimer's disease and potential pitfalls in diagnosis, choice of therapeutic targets, development of drug candidates, and design of clinical trials. Many clinical and experimental studies are ongoing, but we need to acknowledge that a single cure for Alzheimer's disease is unlikely to be found and that the approach to drug development for this disorder needs to be reconsidered. Preclinical research is constantly providing us with new information on pieces of the complex Alzheimer's disease puzzle, and an analysis of this information might reveal patterns of pharmacological interactions instead of single potential drug targets. Several promising randomised controlled trials are ongoing, and the increased collaboration between pharmaceutical companies, basic researchers, and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of Alzheimer's disease.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70119-8

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Alzheimer’s disease
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560

Show all 161 references

Research works printed but not linked: 3

Solomon, 2010, A new target for Alzheimer's disease immunotherapy. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S29
Lenz R, Berry SM, Pritchett YL, et al. Novel investigation of a neuronal nicotinic receptor partial agonist in the treatment of Alzheimer's disease. 11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; Geneva, Switzerland; March 24–27, 2010. P100.
Eriksdotter, 2010, Therapy of Alzheimer's disease with NGF. 11th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2010, Geneva, Switzerland, Neurobiol Aging, 31, S9

Sorted by citations

Items 501–600 of 1,000

Anti-Neuroinflammatory Agents for the Treatment of Alzheimer’s Disease
Zhou, W., & Hu, W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.125 · Cited by 31
Alzheimer’s Disease: Future Treatments
Morley, J. E. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.10.008 · Cited by 31
The Role of Cysteine Protease in Alzheimer Disease
Hasanbašić, S., Jahić, A., Karahmet, E., Sejranic, A., & Prnjavorac, A. (2016) · Materia Socio Medica · doi:10.5455/msm.2016.28.235-238 · Cited by 31
Deep Learning for Alzheimer’s Disease Classification using Texture Features
So, J.-H., Madusanka, N., Choi, H., Choi, B.-K., & Park, H. (2019) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405615666190404163233 · Cited by 31
Therapeutic perspective on vascular cognitive impairment
Toyama, K., Spin, J. M., Mogi, M., & Tsao, P. S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104266 · Cited by 31
Anticholinesterase Activity of Eight Medicinal Plant Species: In Vitro and In Silico Studies in the Search for Therapeutic Agents against Alzheimer’s Disease
Uddin, M. J., Russo, D., Rahman, M. M., Uddin, S. B., Halim, M. A., Zidorn, C., & Milella, L. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9995614 · Cited by 31
Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer’s Disease
Shi, Y., Lv, J., Ling, C., Luo, G., Tao, M., Pan, J., Hu, X., Sheng, J., Zhang, S., Zhou, M., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.722580 · Cited by 31
On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Kriška, J., Heřmanová, Z., Knotek, T., Turečková, J., & Anděrová, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189689 · Cited by 33
Human fetal tau protein isoform: Possibilities for Alzheimer's disease treatment
Milošević, N. J., Petrović, D., Sedmak, G., Vukšić, M., Hof, P. R., & Šimić, G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.001 · Cited by 34
Drug development status for Alzheimer’s disease: present scenario
Misra, S., & Medhi, B. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1316-x · Cited by 31
Original article Paeoniflorin attenuates Aβ 25-35 -induced neurotoxicity in PC12 cells by preventing mitochondrial dysfunction
Li, J., Ji, X., Zhang, J., Shi, G., Xue, Z., & Wang, K. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45569 · Cited by 33
A 4.7-kDa polysaccharide from Panax ginseng suppresses Aβ pathology via mitophagy activation in cross-species Alzheimer’s disease models
Zhang, S., Liu, F., Li, J., Jing, C., Lü, J., Chen, X., Wang, D., Cao, D., Zhao, D., & Sun, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115442 · Cited by 32
Use of Biomarkers in Clinical Trials of Alzheimer Disease
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 32
Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention
Hampel, H. J. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212000579 · Cited by 30
Alzheimer's disease: cost cuts call for novel drugs development and national strategy
Marešová, P., Klímová, B., & Kuča, K. (2015) · Česká a slovenská farmacie · doi:10.36290/csf.2015.005 · Cited by 30
GluN2B-containing NMDA receptors contribute to the beneficial effects of hydrogen sulfide on cognitive and synaptic plasticity deficits in APP/PS1 transgenic mice
Yang, Y., Zhao, Y. H., Yu, B., Xu, G., Wang, W., Zhan, J., Tang, Z., Wang, T., & Wei, B. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.08.033 · Cited by 30
Histone deacetylase inhibitor apicidin increases expression of the α‐secretase ADAM10 through transcription factor USF1‐mediated mechanisms
Hu, X., Zhu, B., Zhao, L., Wang, J., Liu, L., Lai, Y., He, L., Deng, X., & Chen, G. (2016) · The FASEB Journal · doi:10.1096/fj.201600961rr · Cited by 30
Bilingualism for Dementia: Neurological Mechanisms Associated With Functional and Structural Changes in the Brain
Kim, S., Jeon, S. G., Nam, Y., Kim, H. S., Yoo, D., & Moon, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01224 · Cited by 38
Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Štrac, D. Š., Konjevod, M., Perković, M. N., Tudor, L., Erjavec, G. N., & Pivac, N. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200317092310 · Cited by 31
In situ monitoring of protein aggregation via clusteroluminescence
Zhang, Z., Zhu, L., Feng, J., Zhang, H., Zhang, X., Sun, J. Z., & Tang, B. Z. (2022) · Materials Chemistry Frontiers · doi:10.1039/d2qm01032a · Cited by 30
Late-Onset Alzheimer's Disease, Heating up and Foxed by Several Proteins: Pathomolecular Effects of the Aging Process
Perez, F. P., Bose, D., Maloney, B., Nho, K. T., Shah, K., & Lahiri, D. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131544 · Cited by 31
JD-30, an active fraction extracted from Danggui–Shaoyao–San, decreases β-amyloid content and deposition, improves LTP reduction and prevents spatial cognition impairment in SAMP8 mice
Hu, Z.-Y., Liu, G., Cheng, X., Huang, Y. Y., Yang, S., Shan-yi, Q., Sun, L., Zhou, W., & Zhang, Y. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.09.009 · Cited by 30
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Ostrovskaya, R. U., Vakhitova, Y. V., Kuzmina, U. S., Салимгареева, М. Х., Зайнуллина, Л. Ф., Гудашева, Т. А., Вахитов, В. А., & Середенин, С. Б. (2014) · Journal of Biomedical Science · doi:10.1186/s12929-014-0074-2 · Cited by 30
Identification of AChE targeted therapeutic compounds for Alzheimer’s disease: an in-silico study with DFT integration
Rawat, K., Tewari, D., Bisht, A., Chandra, S., Tiruneh, Y. K., Hassan, H. M., Al‐Emam, A., Sindi, E. R., & Al-Dies, A.-A. M. (2024) · Scientific Reports · doi:10.1038/s41598-024-81285-2 · Cited by 35
Alzheimer′s disease: A review of recent developments
Salawu, F., Umar, J., & Olokoba, A. (2011) · Annals of African Medicine · doi:10.4103/1596-3519.82057 · Cited by 29
Amyloid‐β Aggregation with Gold Nanoparticles on Brain Lipid Bilayer
Lee, H., Kim, Y., Park, A., & Nam, J. (2014) · Small · doi:10.1002/smll.201303242 · Cited by 29
Edaravone inhibits the conformational transition of amyloid-β42: insights from molecular dynamics simulations
Liu, F., Ma, Z., Sang, J., & Lu, F. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1632225 · Cited by 29
Associations between the Intake of Different Types of Dairy and Cognitive Performance in Dutch Older Adults: The B-PROOF Study
de Goeij, L. C., van de Rest, O., Feskens, E. J. M., de Groot, C. P. G. M., & Brouwer-Brolsma, E. M. (2020) · Nutrients · doi:10.3390/nu12020468 · Cited by 31
Mouse models of Alzheimer's disease for preclinical research
Watamura, N., Sato, K., & Saido, T. C. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105361 · Cited by 31
Neural Stem Cells in the Treatment of Alzheimer’s Disease: Current Status, Challenges, and Future Prospects
Chen, X., Jiang, S., Wang, R., Bao, X., & Li, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220721 · Cited by 34
Suppressive Effects of SuHeXiang Wan on Amyloid-β42-Induced Extracellular Signal-Regulated Kinase Hyperactivation and Glial Cell Proliferation in a Transgenic Drosophila Model of Alzheimer’s Disease
Park, S. H., Lee, S., Hong, Y. K., Hwang, S., Lee, J. H., Bang, S. M., Kim, Y., Koo, B., Lee, I., & Cho, K. S. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00792 · Cited by 29
Effects of Citicoline as an Adjunct Treatment for Alzheimer’s Disease: A Systematic Review
Piamonte, B. L. C., Espiritu, A. I., & Anlacan, V. M. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200378 · Cited by 29
Design, synthesis and biological evaluation of coumarin derivatives as novel acetylcholinesterase inhibitors that attenuate H2O2-induced apoptosis in SH-SY5Y cells
Yao, D., Wang, J., Wang, G., Jiang, Y., Shang, L., Zhao, Y., Huang, J., Yang, S., Wang, J., & Yu, Y. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.07.013 · Cited by 30
Asiaticoside Mitigates Alzheimer’s Disease Pathology by Attenuating Inflammation and Enhancing Synaptic Function
Liu, S., Chen, L., Li, J., Sun, Y., Xu, Y., Li, Z., Zhu, Z., & Li, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511976 · Cited by 28
Revised criteria for Alzheimer's disease: what are the lessons for clinicians?
Frisoni, G. B., Hampel, H. J., O'Brien, J. T., Ritchie, K. A., & Winblad, B. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70126-0 · Cited by 28
Self-citation
Focused design of polypharmacophoric neuroprotective compounds: Conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole
Махаева, Г. Ф., Sokolov, V. B., Shevtsova, E. F., Ковалева, Н. В., Lushchekina, S. V., Boltneva, N. P., Рудакова, Е. В., Aksinenko, A. Y., Shevtsov, P. N., Евгеньевна, Н. М., et al. (2017) · Pure and Applied Chemistry · doi:10.1515/pac-2017-0308 · Cited by 28
Modulating Aβ aggregation by tyrosol-based ligands: The crucial role of the catechol moiety
Romanucci, V., García‐Viñuales, S., Tempra, C., Bernini, R., Zarrelli, A., Lolicato, F., Milardi, D., & Fabio, G. D. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106434 · Cited by 29
1H-1,2,3-triazole grafted tacrine-chalcone conjugates as potential cholinesterase inhibitors with the evaluation of their behavioral tests and oxidative stress in mice brain cells
Rani, A., Singh, A., Kaur, J., Singh, G., Bhatti, R., Gumede, N. J., Kisten, P., Singh, P., Sumanjit, & Kumar, V. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105053 · Cited by 29
Etiology and management of Alzheimer’s disease: Potential role of gut microbiota modulation with probiotics supplementation
Dasriya, V. L., Samtiya, M., Dhewa, T., Puniya, M., Kumar, S., Ranveer, S. A., Chaudhary, V., Vij, S., Behare, P. V., Singh, N., et al. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.14043 · Cited by 29
Gardenia jasminoides J. Ellis extract alleviated white matter damage through promoting the differentiation of oligodendrocyte precursor cells via suppressing neuroinflammation
Zang, C., Liu, H., Ju, C., Yuan, F., Ning, J., Shang, M., Bao, X., Yu, Y., Yao, X., & Zhang, D. (2022) · Food & Function · doi:10.1039/d1fo02127c · Cited by 28
Neuroprotective effects of resistance physical exercise on the APP/PS1 mouse model of Alzheimer’s disease
Campos, H. C., Ribeiro, D. E., Hashiguchi, D., Glaser, T., Milanis, M. D. S., Gimenes, C., Suchecki, D., Arida, R. M., Ulrich, H., & Longo, B. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1132825 · Cited by 30
Animal models of Alzheimer’s disease: preclinical insights and challenges
Xu, Q., Yang, W., Zhong, M., Lin, Z., Gray, N. E., & Xian, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0001 · Cited by 30
Synthesis of Monomeric Derivatives To Probe Memoquin’s Bivalent Interactions
Bolognesi, M. L., Chiriano, G., Bartolini, M., Mancini, F., Bottegoni, G., Maestri, V., Czvitkovich, S., Windisch, M., Cavalli, A., Minarini, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200691d · Cited by 28
Identification of myo‐inositol hexakisphosphate (IP6) as a β‐secretase 1 (BACE1) inhibitory molecule in rice grain extract and digest
Abe, T. K., & Taniguchi, M. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.01.008 · Cited by 28
Correlations between serum levels of beta amyloid, cerebrospinal levels of tau and phospho tau, and delayed response tasks in young and aged cynomolgus monkeys ( M acaca fascicularis)
Darusman, H. S., Sajuthi, D., Kalliokoski, O., Jacobsen, K. R., Call, J., Schapiro, S. J., GJEDDE, A. H., Abelson, K., & Hau, J. (2013) · Journal of Medical Primatology · doi:10.1111/jmp.12044 · Cited by 27
Paeoniflorin attenuates Aβ25-35-induced neurotoxicity in PC12 cells by preventing mitochondrial dysfunction.
Li, J., Ji, X., Zhang, J., Shi, G., Zhu, X., & Wang, K. (2014) · PubMed · Cited by 28
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27
Investigational medications for treatment of patients with Alzheimer disease.
Potter, P. E. (2010) · PubMed · Cited by 27
Early cost‐utility analysis of general and cerebrospinal fluid‐specific Alzheimer's disease biomarkers for hypothetical disease‐modifying treatment decision in mild cognitive impairment
Handels, R. L. H., Joore, M. A., Tran‐Duy, A., Wimo, A. B., Wolfs, C. A. G., Verhey, F. R. J., & Severens, J. L. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.009 · Cited by 27
In silico to in vitro screening of hydroxypyridinones as acetylcholinesterase inhibitors
Telpoukhovskaia, M. A., Patrick, B. O., Rodríguez‐Rodríguez, C., & Orvig, C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.080 · Cited by 27
Promoter Hypomethylation of TGFBR3 as a Risk Factor of Alzheimer’s Disease: An Integrated Epigenomic-Transcriptomic Analysis
Song, H., Yang, J., & Yu, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.825729 · Cited by 27
New insight into brain disease therapy: nanomedicines-crossing blood–brain barrier and extracellular space for drug delivery
Gu, Z., Chen, H., Zhao, H., Yang, W., Song, Y., Li, X., Wang, Y., Du, D., Liao, H., Pan, W., et al. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2139369 · Cited by 27
Thiadiazole – A promising structure in design and development of anti-Alzheimer agents
Hatami, M., Basri, Z., Sakhvidi, B. K., & Mortazavi, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110027 · Cited by 27
Construction of multiple concentration gradients for single-cell level drug screening
Shen, S., Zhang, F., Zhang, Y., Li, Y., Niu, Y., Pang, L., & Wang, J. (2023) · Microsystems & Nanoengineering · doi:10.1038/s41378-023-00516-0 · Cited by 27
High Resolution Imaging Study of Interactions between the 37 kDa/67 kDa Laminin Receptor and APP, Beta-Secretase and Gamma-Secretase in Alzheimer's Disease
Jovanovic, K., Loos, B., Dias, B. D. C., Penny, C. B., & Weiss, S. F. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100373 · Cited by 26
Transient gamma-secretase inhibition accelerates and enhances fracture repair likely via Notch signaling modulation
Wang, C., Shen, J., Yukata, K., Inzana, J. A., O’Keefe, R. J., Awad, H. A., & Hilton, M. J. (2014) · Bone · doi:10.1016/j.bone.2014.12.007 · Cited by 27
Higher Serum 25-Hydroxyvitamin D and Lower Plasma Glucose Are Associated with Larger Gray Matter Volume but Not with White Matter or Total Brain Volume in Dutch Community-Dwelling Older Adults ,
Brouwer-Brolsma, E. M., van der Zwaluw, N. L., van Wijngaarden, J. P., Dhonukshe-Rutten, R. A. M., Veld, P. H. I. '., Feskens, E. J. M., Smeets, P. A. M., Kessels, R. P. C., van de Rest, O., & de Groot, C. P. G. M. (2015) · Journal of Nutrition · doi:10.3945/jn.115.214197 · Cited by 27
Inhibitory effect of flavonoids on human glutaminyl cyclase
Li, M., Dong, Y., Yu, X., Zou, Y., Zheng, Y., Bu, X., Quan, J., He, Z., & Wu, H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.064 · Cited by 27
Alzheimer’s disease: insights for risk evaluation and prevention in the Chinese population and the need for a comprehensive programme in Hong Kong/China
Avalon Genomics (HK) Limited, S., Yee, A., Tsui, N. B. Y., Chang, Y., Au, C. S., Fok, M., Lau, L. T., Chung, T., Cheng, G. Y.-M., Kwan, R. Y. C., et al. (2018) · Hong Kong Medical Journal · doi:10.12809/hkmj187244 · Cited by 26
Correction: A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease
Parthsarathy, V., McClean, P. L., HÃ¶lscher, C., Taylor, M., Tinker, C. L., Jones, G., Kolosov, O., Salvati, E., Gregori, M., Masserini, M., et al. (2013) · PLoS ONE · doi:10.1371/annotation/57e0a947-8600-4658-b04c-cf7a45c8bd8d · Cited by 27
Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines
Lu, J., Maezawa, I., Weerasekara, S., Erenler, R., Nguyen, T. D. T., Nguyen, J. T., Swisher, L. Z., Li, J., Jin, L., Ranjan, A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.085 · Cited by 26
Low−dose ionizing radiation alleviates Aβ42−induced cell death via regulating AKT and p38 pathways inDrosophilaAlzheimer′s disease models
Hwang, S., Jeong, H., Hong, E., Joo, H. M., Cho, K. S., & Nam, S. Y. (2019) · Biology Open · doi:10.1242/bio.036657 · Cited by 26
Breviscapine exerts neuroprotective effects through multiple mechanisms in APP/PS1 transgenic mice
Zhu, L., Zhang, X.-B., Gu, J.-H., Zeng, Y.-Q., & Li, J. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03698-7 · Cited by 26
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
Kanach, C., Blusztajn, J. K., Fischer, A., & Delalle, I. (2021) · Non-Coding RNA · doi:10.3390/ncrna7010008 · Cited by 25
Evaluation of antioxidant and inhibitory properties of Citrus aurantium L. on the acetylcholinesterase activity and the production of amyloid nano–bio fibrils
Pasandideh, S., & Arasteh, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.04.043 · Cited by 26
In-silico evaluations of the isolated phytosterols from polygonum hydropiper L against BACE1 and MAO drug targets
Ayaz, M., Wadood, A., Sadiq, A., Ullah, F., Anichkina, O. A., & Ghufran, M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1940286 · Cited by 26
Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis
Pang, M., Zhu, L., Gabelle, A., Gafson, A., Platt, R. W., Galvin, J. E., Krolak‐Salmon, P., Rubino, I., de Moor, C., Belachew, S. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12768 · Cited by 30
Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients
Boyd, H., & Booth‐Jones, M. (2012) · Brain Disorders & Therapy · doi:10.4172/bdt.1000101 · Cited by 25
Medical Foods for Alzheimerʼs Disease
Shah, R. C. (2011) · Drugs & Aging · doi:10.2165/11587380-000000000-00000 · Cited by 26
MRZ-99030 – A novel modulator of Aβ aggregation: II – Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice
Rammes, G., Gravius, A., Ruitenberg, M., Wegener, N., Chambon, C., Sroka, K., Jeggo, R., Staniaszek, L. E., Spanswick, D. C., O‘Hare, E., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.037 · Cited by 51
Fenofibrate reduces amyloidogenic processing of APP in APP/PS1 transgenic mice via PPAR‐α/PI3‐K pathway
Zhang, H., Gao, Y., Qiao, P., Zhao, F., & Yan, Y. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.10.004 · Cited by 26
Prevention strategies for Alzheimer’s disease
Gauthier, S. G., Wu, L., Rosa‐Neto, P., & Jia, J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-13 · Cited by 31
Past to Future: What Animal Models Have Taught Us About Alzheimer’s Disease
Martini, A. C., Forner, S., Trujillo‐Estrada, L., Baglietto‐Vargas, D., & LaFerla, F. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179917 · Cited by 27
Amyloid burden and white matter hyperintensities mediate age-related cognitive differences
Dupont, P. S., Bocti, C., Joannette, M., Lavallée, M. M., Nikelski, J., Vallet, G. T., Chertkow, H., & Joubert, S. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.025 · Cited by 25
Inhibition of Smad3 in macrophages promotes Aβ efflux from the brain and thereby ameliorates Alzheimer's pathology
Xu, L., Pan, C., Wu, X., Song, J., Meng, P., Li, L., Wang, L., Zhang, Z., & Zhang, Z.-Y. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.03.013 · Cited by 27
Hesperetin attenuates cognitive dysfunction via SIRT6/NLRP3 pathway in scopolamine-induced mice
Jing, S., Wang, X., Zhang, Z., Cao, D., Huang, K., Wang, Y., Liu, Z., Su, S., & Wang, Q. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01250-2 · Cited by 24
3‐(2,4‐Dimethoxybenzylidene)‐anabaseine: A promising candidate drug for Alzheimer's disease?
Zawieja, P. P., Kornprobst, J., & Métais, P. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00827.x · Cited by 25
Biomarker trajectories across stages of Alzheimer disease
Frisoni, G. B. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.81 · Cited by 25
Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review)
Hassan, M., Abbas, Q., Seo, S., Shahzadi, S., Alashwal, H., Zaki, N., Iqbal, Z., & Moustafa, A. A. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9044 · Cited by 24
Long-term medical costs of Alzheimer’s disease: matched cohort analysis
Sopina, L., Spackman, E., Martikainen, J. A., Waldemar, G., & Sørensen, J. R. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-1004-0 · Cited by 25
Enzyme Inhibitory Radicinol Derivative from Endophytic fungus Bipolaris sorokiniana LK12, Associated with Rhazya stricta
Khan, A. L., Ali, L., Hussain, J., Rizvi, T. S., Al‐Harrasi, A., & Lee, I. (2015) · Molecules · doi:10.3390/molecules200712198 · Cited by 25
Development of BODIPY-based fluorescent probes for imaging Aβ aggregates and lipid droplet viscosity
Li, K., Wang, Y., Li, Y., Shi, W., & Yan, J. (2024) · Talanta · doi:10.1016/j.talanta.2024.126362 · Cited by 24
Dioscin Protects against Aβ1–42 Oligomers-Induced Neurotoxicity via the Function of SIRT3 and Autophagy
Zhang, Z., Han, K., Wang, C., Sun, C., & Jia, N. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00046 · Cited by 24
Amino acid-functionalized chitosan beads for in vitro copper ions uptake in the presence of histidine
Taketa, T. B., Mahl, C. R. A., Calais, G. B., & Beppu, M. M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.08.017 · Cited by 23
Research progress of the CXCR4 mechanism in Alzheimer's disease
Wang, Q., Fang, C., Huang, X., & Xue, L. (2022) · Ibrain · doi:10.1002/ibra.12026 · Cited by 24
Autophagy Regulation Influences β-Amyloid Toxicity in Transgenic Caenorhabditis elegans
Lin, H., Gao, Y., Zhang, C., Ma, B., Wu, M., Cui, X., & Wang, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.885145 · Cited by 24
Efficacy and safety of 3‐n‐butylphthalide for the treatment of cognitive impairment: A systematic review and meta‐analysis
Zhou, Q., Han, C., Xia, Y., Wan, F. J., Yin, S., Li, Y., Kou, L., Chi, X., Hu, J., Sun, Y., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13952 · Cited by 26
Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer’s disease
Honarnejad, K., Daschner, A., Gehring, A. P., Szybińska, A., Giese, A., Kuźnicki, J., Bracher, F., & Herms, J. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.132 · Cited by 24
Next generation therapeutics for Alzheimer's disease
Bredesen, D. E., & John, V. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202307 · Cited by 25
Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders
Araki, W., Hattori, K., Kanemaru, K., Yokoi, Y., Omachi, Y., Takano, H., Sakata, M., Yoshida, S., Tsukamoto, T., Murata, M., et al. (2017) · Biomarker Research · doi:10.1186/s40364-017-0108-5 · Cited by 24
Aβ-binding with alcohol dehydrogenase drives Alzheimer's disease pathogenesis: A review
Ye, Z., Liu, Y., Jin, X., Wu, Y., Zhao, H., Gao, T., Deng, Q., Cheng, J., Lin, J., & Tong, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130580 · Cited by 23
Pharmacodynamics of Cholinesterase Inhibitors Suggests Add-on Therapy with a Low-Dose Carbamylating Inhibitor in Patients on Long-Term Treatment with Rapidly Reversible Inhibitors
Darreh‐Shori, T., Hosseini, S. M., & Nordberg, A. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130845 · Cited by 23
Uncertainty and health literacy in dementia care
Lo, R. Y. (2019) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_116_19 · Cited by 23
Hologram QSAR Models of 4-[(Diethylamino)methyl]-phenol Inhibitors of Acetyl/Butyrylcholinesterase Enzymes as Potential Anti-Alzheimer Agents
Souza, S. D. D., de Souza, A. M. T., de Sousa, A. C. C., Sodero, A. C. R., Cabral, L. M., Albuquerque, M. G., Castro, H. C., & Rodrigues, C. R. (2012) · Molecules · doi:10.3390/molecules17089529 · Cited by 23
The selective and competitive N-methyl-D-aspartate receptor antagonist, (−)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-β in mice
Bicca, M. A., Figueiredo, C. P., Piermartiri, T., Meotti, F. C., Bouzon, Z. L., Tasca, C. I., Medeiros, R., & Calixto, J. Β. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.038 · Cited by 23
Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150826 · Cited by 24
PP2A Ligand ITH12246 Protects against Memory Impairment and Focal Cerebral Ischemia in Mice
Lorrio, S., Romero, A., González‐Lafuente, L., Lajarín-Cuesta, R., Martínez-Sanz, F. J., Estrada, M., Samadi, A., Marco, J. L., Rodrı́guez-Franco, M. I., Villarroya, M., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400050p · Cited by 23
Vincamine alleviates amyloid-β 25-35 peptides-induced cytotoxicity in PC12 cells
Han, J., Qu, Q., Qiao, J., & Zhang, J. (2016) · Pharmacognosy Magazine · doi:10.4103/0973-1296.196309 · Cited by 22
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
Perhoč, A. B., Barilar, J. O., Knezović, A., Farkaš, V., Bagarić, R., Švarc, A., Grünblatt, E., Riederer, P., & Šalković‐Petrišić, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.018 · Cited by 23
Pharmacotherapy for dementia
Youn, H., & Jeong, H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.12.758 · Cited by 23

Authors: Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M.
Affiliations: University of Perugia (IT)
University of Eastern Finland (FI)
Karolinska Institutet (SE)
Corresponding author: Winblad, Bengt
ORCID: Mangialasche, Francesca
Solomon, Alina
Winblad, Bengt
Mecocci, Patrizia
Kivipelto, Miia
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2010-07
Volume: 9
Issue: 7
Pages: 702-716
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(10)70119-8
OpenAlex: W2129267808
Cited by: 1,217
References: 161
Citations by year: 2026: 31 · 2025: 47 · 2024: 53 · 2023: 45 · 2022: 91 · 2021: 80 · 2020: 69 · 2019: 77 · 2018: 82 · 2017: 79 · 2016: 78 · 2015: 89 · 2014: 121 · 2013: 97 · 2012: 80
FWCI: 8.96
Type: journal article
Language: en
Update notices: erratum (2011-06-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, clinical trials, disease-modifying therapy, symptomatic treatment, therapeutic target, pathogenesis, dementia, drug interactions, randomized controlled trials, translational research
MeSH terms: Alzheimer Disease, Clinical Trials as Topic, Humans, Antipsychotic Agents, Drug Design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer’s disease: Clinical trials and drug development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks